Global 13-Valent Pneumococcal Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 73

Published Date: 19 Jan 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global 13-Valent Pneumococcal Conjugate Vaccine market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

The Global Info Research report includes an overview of the development of the 13-Valent Pneumococcal Conjugate Vaccine industry chain, the market status of Hospital (Vials, Pre-filled), Clinic (Vials, Pre-filled), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of 13-Valent Pneumococcal Conjugate Vaccine.

Regionally, the report analyzes the 13-Valent Pneumococcal Conjugate Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global 13-Valent Pneumococcal Conjugate Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:
The report presents comprehensive understanding of the 13-Valent Pneumococcal Conjugate Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the 13-Valent Pneumococcal Conjugate Vaccine industry.

The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Vials, Pre-filled).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the 13-Valent Pneumococcal Conjugate Vaccine market.

Regional Analysis: The report involves examining the 13-Valent Pneumococcal Conjugate Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the 13-Valent Pneumococcal Conjugate Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to 13-Valent Pneumococcal Conjugate Vaccine:
Company Analysis: Report covers individual 13-Valent Pneumococcal Conjugate Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards 13-Valent Pneumococcal Conjugate Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).

Technology Analysis: Report covers specific technologies relevant to 13-Valent Pneumococcal Conjugate Vaccine. It assesses the current state, advancements, and potential future developments in 13-Valent Pneumococcal Conjugate Vaccine areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the 13-Valent Pneumococcal Conjugate Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation
13-Valent Pneumococcal Conjugate Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.

Market segment by Type
Vials
Pre-filled

Market segment by Application
Hospital
Clinic
CDC

Major players covered
Pfizer
Kangtai
Walvax Biotechnology

Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe 13-Valent Pneumococcal Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of 13-Valent Pneumococcal Conjugate Vaccine, with price, sales, revenue and global market share of 13-Valent Pneumococcal Conjugate Vaccine from 2019 to 2024.
Chapter 3, the 13-Valent Pneumococcal Conjugate Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 13-Valent Pneumococcal Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and 13-Valent Pneumococcal Conjugate Vaccine market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of 13-Valent Pneumococcal Conjugate Vaccine.
Chapter 14 and 15, to describe 13-Valent Pneumococcal Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of 13-Valent Pneumococcal Conjugate Vaccine
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 Vials
        1.3.3 Pre-filled
    1.4 Market Analysis by Application
        1.4.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
        1.4.4 CDC
    1.5 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size & Forecast
        1.5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2019-2030)
        1.5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
        2.1.4 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Pfizer Recent Developments/Updates
    2.2 Kangtai
        2.2.1 Kangtai Details
        2.2.2 Kangtai Major Business
        2.2.3 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
        2.2.4 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Kangtai Recent Developments/Updates
    2.3 Walvax Biotechnology
        2.3.1 Walvax Biotechnology Details
        2.3.2 Walvax Biotechnology Major Business
        2.3.3 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
        2.3.4 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 Walvax Biotechnology Recent Developments/Updates

3 Competitive Environment: 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer
    3.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2023
        3.4.2 Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2023
    3.5 13-Valent Pneumococcal Conjugate Vaccine Market: Overall Company Footprint Analysis
        3.5.1 13-Valent Pneumococcal Conjugate Vaccine Market: Region Footprint
        3.5.2 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
        3.5.3 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
        4.1.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2019-2030)
    4.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030)
    4.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030)
    4.5 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030)
    4.6 Middle East and Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2019-2030)
    5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2019-2030)
    6.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
        7.3.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
        8.3.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
        9.3.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
        10.3.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
        11.3.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
    12.2 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
    12.3 13-Valent Pneumococcal Conjugate Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of 13-Valent Pneumococcal Conjugate Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of 13-Valent Pneumococcal Conjugate Vaccine
    13.3 13-Valent Pneumococcal Conjugate Vaccine Production Process
    13.4 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
    14.3 13-Valent Pneumococcal Conjugate Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Table 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
    Table 4. Pfizer Major Business
    Table 5. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
    Table 6. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 7. Pfizer Recent Developments/Updates
    Table 8. Kangtai Basic Information, Manufacturing Base and Competitors
    Table 9. Kangtai Major Business
    Table 10. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
    Table 11. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 12. Kangtai Recent Developments/Updates
    Table 13. Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
    Table 14. Walvax Biotechnology Major Business
    Table 15. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
    Table 16. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
    Table 17. Walvax Biotechnology Recent Developments/Updates
    Table 18. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024) & (K Units)
    Table 19. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
    Table 20. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2019-2024) & (US$/Unit)
    Table 21. Market Position of Manufacturers in 13-Valent Pneumococcal Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
    Table 22. Head Office and 13-Valent Pneumococcal Conjugate Vaccine Production Site of Key Manufacturer
    Table 23. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
    Table 24. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
    Table 25. 13-Valent Pneumococcal Conjugate Vaccine New Market Entrants and Barriers to Market Entry
    Table 26. 13-Valent Pneumococcal Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
    Table 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 28. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 29. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 30. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 31. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2019-2024) & (US$/Unit)
    Table 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2025-2030) & (US$/Unit)
    Table 33. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 34. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 35. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2019-2024) & (USD Million)
    Table 36. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2025-2030) & (USD Million)
    Table 37. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2019-2024) & (US$/Unit)
    Table 38. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2025-2030) & (US$/Unit)
    Table 39. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 40. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 41. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2019-2024) & (USD Million)
    Table 42. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2025-2030) & (USD Million)
    Table 43. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2019-2024) & (US$/Unit)
    Table 44. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2025-2030) & (US$/Unit)
    Table 45. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 46. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 47. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 48. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 49. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 50. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 51. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 52. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 53. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 54. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 55. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 56. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 57. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 58. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 59. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 60. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 61. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 62. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 63. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 64. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 65. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 66. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 67. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 68. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 69. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 70. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 71. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 72. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 73. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
    Table 74. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
    Table 75. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
    Table 76. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
    Table 77. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
    Table 78. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
    Table 79. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
    Table 80. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
    Table 81. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
    Table 82. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
    Table 83. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
    Table 84. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
    Table 85. 13-Valent Pneumococcal Conjugate Vaccine Raw Material
    Table 86. Key Manufacturers of 13-Valent Pneumococcal Conjugate Vaccine Raw Materials
    Table 87. 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
    Table 88. 13-Valent Pneumococcal Conjugate Vaccine Typical Customers
List of Figures
    Figure 1. 13-Valent Pneumococcal Conjugate Vaccine Picture
    Figure 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
    Figure 3. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type in 2023
    Figure 4. Vials Examples
    Figure 5. Pre-filled Examples
    Figure 6. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
    Figure 7. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application in 2023
    Figure 8. Hospital Examples
    Figure 9. Clinic Examples
    Figure 10. CDC Examples
    Figure 11. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
    Figure 12. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
    Figure 13. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2019-2030) & (K Units)
    Figure 14. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2019-2030) & (US$/Unit)
    Figure 15. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2023
    Figure 16. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Manufacturer in 2023
    Figure 17. Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
    Figure 18. Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 19. Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2023
    Figure 20. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 21. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 22. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 23. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 24. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 25. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 26. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
    Figure 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 28. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type (2019-2030)
    Figure 29. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2019-2030) & (US$/Unit)
    Figure 30. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 31. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application (2019-2030)
    Figure 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2019-2030) & (US$/Unit)
    Figure 33. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 34. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 35. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 36. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 37. United States 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 38. Canada 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 39. Mexico 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 40. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 41. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 42. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 43. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 44. Germany 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 45. France 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 46. United Kingdom 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 47. Russia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 48. Italy 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 49. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 50. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 51. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 52. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 53. China 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 54. Japan 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 55. Korea 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 56. India 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 57. Southeast Asia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 58. Australia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 59. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 60. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 61. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
    Figure 62. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
    Figure 63. Brazil 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 64. Argentina 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 65. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
    Figure 66. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
    Figure 67. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
    Figure 68. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
    Figure 69. Turkey 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 70. Egypt 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 71. Saudi Arabia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 72. South Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2019-2030) & (USD Million)
    Figure 73. 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
    Figure 74. 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
    Figure 75. 13-Valent Pneumococcal Conjugate Vaccine Market Trends
    Figure 76. Porters Five Forces Analysis
    Figure 77. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Conjugate Vaccine in 2023
    Figure 78. Manufacturing Process Analysis of 13-Valent Pneumococcal Conjugate Vaccine
    Figure 79. 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain
    Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 81. Direct Channel Pros & Cons
    Figure 82. Indirect Channel Pros & Cons
    Figure 83. Methodology
    Figure 84. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer
Kangtai
Walvax Biotechnology

Related Reports

Global 13-Valent Pneumococcal Conjugate Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Global 13-Valent Pneumococcal Conjugate Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

date 29 Aug 2023

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global 13-Valent Pneumococcal Conjugate Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.

Global 13-Valent Pneumococcal Conjugate Vaccine Supply, Demand and Key Producers, 2023-2029

Global 13-Valent Pneumococcal Conjugate Vaccine Supply, Demand and Key Producers, 2023-2029

date 29 Aug 2023

date Pharma & Healthcare

The global 13-Valent Pneumococcal Conjugate Vaccine market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Product Tags

13-Valent Pneumococcal Conjugate Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>